FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2745803145> ?p ?o ?g. }

• W2745803145 endingPage "73016" @default.
• W2745803145 startingPage "73009" @default.
• W2745803145 abstract "// Hyun Joo Jang 1 , Bum Jun Kim 2, 3 , Jung Han Kim 2 and Hyeong Su Kim 2 1 Division of Gastroenterology, Department of Internal Medicine, Dongtan Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Hwasung 18450, Republic of Korea 2 Division of Hemato-Oncology, Department of Internal Medicine, Kangnam Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Seoul 07441, Republic of Korea 3 Department of Internal Medicine, Korean Armed Forces Capital Hospital, The Armed Forces Medical Command, Sungnam 13574, Republic of Korea Correspondence to: Jung Han Kim, email: harricil@hotmail.com Hyeong Su Kim, email: nep2n@hallym.or.kr Keywords: colorectal cancer, bevacizumab, irinotecan, meta-analysis Received: May 16, 2017      Accepted: August 06, 2017      Published: August 17, 2017 ABSTRACT Bevacizumab has shown survival benefits when added to chemotherapy in patients with metastatic colon cancer (mCRC). However, the efficacy of bevacizumab may depend on the accompanying chemotherapeutic regimen. We performed this meta-analysis to examine the impact of the choice of chemotherapy regimen on the survival benefits of bevacizumab in the first-line treatment for patients with mCRC. Electric databases were searched for eligible randomized trials. From 9 studies, 3,710 patients with mCRC were included in the meta-analysis of hazard ratios (HRs) for progression-free survival (PFS) or overall survival (OS). Compared with chemotherapy alone, the addition of bevacizumab to chemotherapy significantly prolonged PFS (HR = 0.66 [95% confidence interval (CI), 0.55–0.77], P < 0.0001) and OS (HR = 0.84 [95% CI, 0.77–0.92], P = 0.0001). In the subgroup analysis according to the chemotherapeutic regimens, bevacizumab showed both PFS (HR = 0.57 [95% CI, 0.41–0.77], P = 0.0004) and OS (HR = 0.79 [95% CI, 0.67–0.93], P = 0.004) advantages only in combination with irinotecan-based regimen. In conclusion, this meta-analysis confirms that the addition of bevacizumab to chemotherapy significantly prolongs PFS and OS in the first-line treatment for mCRC. The subgroup analyses suggest that irinotecan-based regimen may be a better partner of bevacizumab in terms of both PFS and OS." @default.
• W2745803145 created "2017-08-31" @default.
• W2745803145 creator A5033087588 @default.
• W2745803145 creator A5044201544 @default.
• W2745803145 creator A5044483735 @default.
• W2745803145 creator A5063892435 @default.
• W2745803145 date "2017-08-17" @default.
• W2745803145 modified "2023-10-12" @default.
• W2745803145 title "The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials" @default.
• W2745803145 cites W1757407923 @default.
• W2745803145 cites W1870066362 @default.
• W2745803145 cites W2012852444 @default.
• W2745803145 cites W2048067273 @default.
• W2745803145 cites W2053083499 @default.
• W2745803145 cites W2057282229 @default.
• W2745803145 cites W2083558962 @default.
• W2745803145 cites W2085705101 @default.
• W2745803145 cites W2087163755 @default.
• W2745803145 cites W2093152548 @default.
• W2745803145 cites W2096651590 @default.
• W2745803145 cites W2098354753 @default.
• W2745803145 cites W2105683151 @default.
• W2745803145 cites W2109740395 @default.
• W2745803145 cites W2119605658 @default.
• W2745803145 cites W2121368761 @default.
• W2745803145 cites W2122152991 @default.
• W2745803145 cites W2125447919 @default.
• W2745803145 cites W2125923056 @default.
• W2745803145 cites W2128447158 @default.
• W2745803145 cites W2130867283 @default.
• W2745803145 cites W2134142320 @default.
• W2745803145 cites W2138075845 @default.
• W2745803145 cites W2139168548 @default.
• W2745803145 cites W2143743735 @default.
• W2745803145 cites W2156575195 @default.
• W2745803145 cites W2157769714 @default.
• W2745803145 cites W2162313061 @default.
• W2745803145 cites W2168579528 @default.
• W2745803145 cites W2235523093 @default.
• W2745803145 cites W2327814330 @default.
• W2745803145 cites W2507923170 @default.
• W2745803145 cites W2917116917 @default.
• W2745803145 doi "https://doi.org/10.18632/oncotarget.20314" @default.
• W2745803145 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5641187" @default.
• W2745803145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29069844" @default.
• W2745803145 hasPublicationYear "2017" @default.
• W2745803145 type Work @default.
• W2745803145 sameAs 2745803145 @default.
• W2745803145 citedByCount "26" @default.
• W2745803145 countsByYear W27458031452018 @default.
• W2745803145 countsByYear W27458031452019 @default.
• W2745803145 countsByYear W27458031452020 @default.
• W2745803145 countsByYear W27458031452021 @default.
• W2745803145 countsByYear W27458031452022 @default.
• W2745803145 countsByYear W27458031452023 @default.
• W2745803145 crossrefType "journal-article" @default.
• W2745803145 hasAuthorship W2745803145A5033087588 @default.
• W2745803145 hasAuthorship W2745803145A5044201544 @default.
• W2745803145 hasAuthorship W2745803145A5044483735 @default.
• W2745803145 hasAuthorship W2745803145A5063892435 @default.
• W2745803145 hasBestOaLocation W27458031451 @default.
• W2745803145 hasConcept C121608353 @default.
• W2745803145 hasConcept C126322002 @default.
• W2745803145 hasConcept C143998085 @default.
• W2745803145 hasConcept C168563851 @default.
• W2745803145 hasConcept C207103383 @default.
• W2745803145 hasConcept C2776694085 @default.
• W2745803145 hasConcept C2777802072 @default.
• W2745803145 hasConcept C2778336483 @default.
• W2745803145 hasConcept C2780259306 @default.
• W2745803145 hasConcept C2781413609 @default.
• W2745803145 hasConcept C44249647 @default.
• W2745803145 hasConcept C526805850 @default.
• W2745803145 hasConcept C71924100 @default.
• W2745803145 hasConceptScore W2745803145C121608353 @default.
• W2745803145 hasConceptScore W2745803145C126322002 @default.
• W2745803145 hasConceptScore W2745803145C143998085 @default.
• W2745803145 hasConceptScore W2745803145C168563851 @default.
• W2745803145 hasConceptScore W2745803145C207103383 @default.
• W2745803145 hasConceptScore W2745803145C2776694085 @default.
• W2745803145 hasConceptScore W2745803145C2777802072 @default.
• W2745803145 hasConceptScore W2745803145C2778336483 @default.
• W2745803145 hasConceptScore W2745803145C2780259306 @default.
• W2745803145 hasConceptScore W2745803145C2781413609 @default.
• W2745803145 hasConceptScore W2745803145C44249647 @default.
• W2745803145 hasConceptScore W2745803145C526805850 @default.
• W2745803145 hasConceptScore W2745803145C71924100 @default.
• W2745803145 hasIssue "42" @default.
• W2745803145 hasLocation W27458031451 @default.
• W2745803145 hasLocation W27458031452 @default.
• W2745803145 hasLocation W27458031453 @default.
• W2745803145 hasLocation W27458031454 @default.
• W2745803145 hasOpenAccess W2745803145 @default.
• W2745803145 hasPrimaryLocation W27458031451 @default.
• W2745803145 hasRelatedWork W2010928484 @default.
• W2745803145 hasRelatedWork W2014795358 @default.
• W2745803145 hasRelatedWork W2050348440 @default.
• W2745803145 hasRelatedWork W2051540233 @default.

• next